NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2025
0mins
Source: Globenewswire
Alzheimer's Disease Biomarker Findings: NewAmsterdam Pharma's obicetrapib treatment shows significant reductions in Alzheimer's disease biomarkers, particularly in ApoE4 carriers, suggesting a potential preventive strategy for Alzheimer's disease alongside cardiovascular benefits.
Upcoming Presentation: The full results of the Alzheimer’s sub-study will be presented at the Alzheimer’s Association International Conference in Toronto in July 2025, highlighting the implications for patients at risk of Alzheimer's disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
